Keywords: pharming, enters, 30m, hae, drug, accord, leiden
Pharming enters $30M HAE drug accord
Article | 13 February 2006
Leiden, the Netherlands-based biotechology group Pharming NV has signed a strategic partnering agreement with affiliates of Paul Royalty Fund II ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
